Product pipeline

• + Acromegaly - Octreotide
• + Prostate cancer - PCK3145
• + Prostate cancer - Goserelin
• + Cancer - NGR-Delivery Technology
• + HIV/AIDS - Protease Inhibitors
• + HIV/AIDS - Integrase Inhibitors
• + HIV/AIDS - Entry Inhibitors
• + HCV - Polymerase Inhibitors
• + HCV - Entry Inhibitors
• + Influenza A - M2 Proton Channel Inhibitors
• + Diagnostic - PSP94
• + Diagnostic - Colopath® / ColorectAlert™
• + Scientific library

Prostate cancer - PCK3145

Ambrilia’s PCK3145 is an anti-cancer peptide derived from one of the predominant protein found in the human seminal fluid and which is being developed for the treatment of advanced metastatic prostate cancer. The mechanism of action suggests that PCK3145 exhibits both an anti-metastatic effect, therefore slowing down the process by which the cancer spreads from the primary tumor to other locations in the body, and an anti-angiogenesis effect, attacking directly metastases. This is crucial since in most cancers it is not the primary tumor that kills the patient but rather the metastases.

PCK3145’s mechanism of action was elucidated in collaboration with Dr. Richard Béliveau, Director, Laboratory of Molecular Medicine, Hôpital Sainte-Justine and Université du Québec à Montréal.

Integrative model of PCK3145 mechanism of action (PDF 360 Kb)

PCK3145 could potentially be a very efficient treatment and the latest studies demonstrated that the drug is well tolerated and safe for patients. Furthermore, the anti-metastatic effect of PCK3145 would suggest the potential utility of the drug in other types of cancer such as breast cancer, colon cancer and lung cancer.

Clinical development

In April, Ambrilia announced the positive findings of a Phase I/II study conducted at the Memorial Sloan Kettering Cancer Center, New York City, which showed that its therapeutic peptide drug PCK3145 had clinical activity in metastatic prostate cancer patients. PCK3145 was found to be safe and well tolerated, and was shown to increasePSA doubling time and down-regulate MMP-9. Disease stabilization as assessed by time to radiographic progression was also observed in several patients. This study of 28 metastatic hormone refractory patientswas led by co-investigators Drs. Susan Slovin and Howard Scher.

These data are encouraging and warrant further development of the drug in late-stage prostate cancer patients, who have very limited treatment options.

Licensing opportunities

Ambrilia’s PCK3145 anti-cancer peptide is available for licensing. For more information, please contact:

Daniel Böck, Ph.D.
Vice-President, Business Development and Licensing
Tel.: 514 751-2003 ext. 236
E-mail: dbock@ambrilia.com